Abstract 2179P
Background
In cancer immunotherapy, the epidemiology of irAE in real-life is poorly understood due to limited reporting and compartmentalization of the healthcare system. This study aims to determine the incidence, severity, and consequences of irAE of all grades in patients initiating cancer immunotherapy using a prospective and multicenter cohort.
Methods
The study will include 900 patients treated with ipilimumab and/or nivolumab in a French real-life, longitudinal, observational, and e-cohort study. Data collection is conducted through digital questionnaires, with physician validation and soon-to-be-matched analysis with the National Health System.
Results
658 patients (70.7% men, 29.3% women, mean age 66) were followed up for a median of 198 days. Of those, 75.8% were treated with Nivolumab alone, 1.2% with Ipilimumab alone, and 22.9% with a combination. Lung cancer, clear cell renal carcinoma, and melanoma were the most common histological types treated. At analysis, 115 immune related adverse events (irAE) were observed in 11.7% of patients (30.5 irAE/100 patient/years) at a median time of 155 (+/- 128) days after initiating immunotherapy. Approximately 30% of reported irAE were rheumatological, and the remaining cases included: colitis (15), hepatitis (8), pancreatitis (2), ileitis (1), myocarditis (2), nephritis (2), immuno-induced pneumopathy (3), macrophage activation syndrome (1), type 1 diabetes (2), hypophysitis (3), adrenal insufficiency (9), thyroid disorder (15), bullous pemphigoid (1), uveitis (1), and other autoimmune manifestations (23). 40 patients discontinued immunotherapy due to irAE, and treatment with corticosteroids was administered in 44 patients (57.1%). Methotrexate (n=1), infliximab (n=3), and abatacept (n=1) were also used to treat specific irAE. One patient died as a result of irAE (colitis).
Conclusions
The preliminary results of this prospective study, using an original patient-centered methodology, confirm the expected incidence of secondary autoimmune events related to immunotherapy. Further inclusions and matching with the SNDS database will allow for the completion of these initial analyses if necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BMS does not have access to the data and does not contribute to its analysis or interpretation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07